Procter & Gamble Health Limited (PGHL) today announced its financial results for the second quarter ended September 30, 2026. The company delivered sales of ₹376 crores, up 18% versus a year ago, driven by strong brand fundamentals, superior retail execution, positive consumer response to new innovations and strengthened go-to-market capabilities. Reported Profit After Tax (PAT) stood at ₹112 crores, up 26% versus a year ago, led by growth in sales and productivity across the value chain.

Strong Brand Fundamentals

The growth reflects the positive response of consumers, patients, and healthcare professionals (HCPs) to PGHL’s science-backed superior healthcare products and innovations amid growing consumer focus on preventive health. Milind Thatte, Managing Director, P&G Health India, said, “We have delivered another strong quarter with double-digit topline and bottom-line growth, continuing the momentum of the previous quarters.”

Retail Execution and Innovations

The impact of PGHL’s strong retail execution, new consumer communication, and HCP awareness initiatives, along with strengthened go-to-market and supply chain capabilities, played a crucial role in the company’s performance. As a result, PGHL is delivering balanced growth and value creation for all its stakeholders.

About Procter & Gamble Health Limited: Procter & Gamble Health Limited is one of India’s largest vitamins, minerals, and supplements (VMS) companies manufacturing and marketing VMS products for a healthy lifestyle and improved quality of life, including Neurobion, Livogen, SevenSeas, Evion, Polybion, and Nasivion. For the latest news and information, please visit www.pghealthindia.com.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Procter & Gamble Health Limited

Procter & Gamble Health Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Procter falls 23.5% over three months and has not found a floor yet. D/E of 0.00 and a 3.01% dividend yield give the balance sheet a decent cushion. Premium net margins of 24.9% demonstrate strong cost discipline and a wide competitive moat. The stock sits at 22% of its 52-week range, close to annual lows. Historically, value investors build positions at these levels — though cheap stocks can stay cheap. Revenue grows at 8.2% and profits at 19.3% CAGR, with D/E of 0.00. Meanwhile, the stock dips 23.5% in three months without any fundamental deterioration. Consequently, the stock quietly becomes cheaper relative to earnings power. For long-term investors, that is a feature. Check Fundamentals of Procter & Gamble Health Limited.

Hikal Limited (NSE: HIKAL) has signed a multi-year contract development and manufacturing (CDMO) contract with a leading Europe-based agrochemical company. This contract follows successful process development and scale-up of a new product, marking a key commercial milestone for Hikal’s Crop Protection business.

Strategic Partnership

The contract, signed by Hikal’s Crop Protection division, covers the CDMO of a specialised agrochemical product. Hikal undertook process development and scale-up for this product. The commercial launch is expected towards the end of FY 2026–27, with volumes anticipated to grow progressively as regulatory approvals are secured across global markets.

Strengthening Capabilities

This partnership underscores Hikal’s capabilities in process development and commercialisation, demonstrating its ability to translate customer requirements into long-term manufacturing opportunities. It also strengthens Hikal’s Crop Protection business by expanding its portfolio of specialised offerings for global customers.

Forward-Looking Statement

Commenting on the development, Mr. Sameer Hiremath, Chairman & Managing Director, Hikal Limited, said: “This contract marks an important milestone for our Crop Protection business, converting nearly three years of collaborative development and scale-up into a long-term commercial partnership. It demonstrates Hikal’s ability to combine deep technical expertise with reliable manufacturing capabilities to take complex products from development to commercial supply. We are well positioned to support the planned launch and progressive expansion of supplies across global markets.”

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Hikal Limited

Hikal Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Hikal holds in the upper half of its 52-week range, a sign the market backs the stock. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. 4 loss quarters over five years is a serious red flag — earnings quality is poor and recovery is not guaranteed. The stock holds at 60% of its 52-week range with RSI at 48. In other words, neither side has a clear edge right now. The stock holds up despite -5.4% revenue growth and a PEG of 99.00. That could signal an early turnaround. Alternatively, index flows simply support the price. Watch whether analysts revise estimates upward — that is the real signal. Check Fundamentals of Hikal Limited.

Sai Parenterals Limited (NSE: SAIPARENT) has announced its un-audited financial results for the quarter and half-year ended 30th September 2026, showcasing significant growth and strategic advancements. Revenue from operations stood at Rs. 196.1 crore, up 9.0% quarter-over-quarter (QoQ) from Rs. 179.9 crore in Q1FY27. The first half of FY27 revenue of Rs. 376.0 crore represents approximately 50% of the FY27 revenue target of Rs. 750 crore, ahead of the guided 45:55 phasing between the two halves.

Key Financial Highlights

Gross profit stood at Rs. 93.1 crore, up 26.4% QoQ, with gross margin rising to 47.5% from 40.9% in Q1FY27. The improvement reflects tighter inventory management: higher-cost inventory from earlier periods was consumed, and first-in, first-out controls were introduced on a new ERP system. EBITDA stood at Rs. 41.4 crore, up 67.4% QoQ, with EBITDA margin at 21.1% against 13.7% in Q1FY27. Despite a more than threefold sequential rise in depreciation, PAT grew 32.7% QoQ to Rs. 10.5 crore in Q2FY27.

Strategic Developments

Following shareholders’ approval of the variation in the objects of the issue, the Company has completed the acquisition of 60% stakes in Saicriti Pharma Private Limited and Prathyak Laboratories Private Limited. It invested Rs. 98.8 crore of IPO proceeds: Rs. 83.83 crore in Saicriti and Rs. 15 crore in Prathyak. The purpose for which the IPO funds were raised remains unchanged: EU-GMP compliant injectable capacity for regulated markets, and a dedicated research and development platform.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Sai Parenterals Limited

Sai Parenterals Limited belongs to the Healthcare › Drug Manufacturers – General sector. Here’s a quick read on where the business and the stock stand today.

Sai falls 12.4% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue grows at 126.1% and profits at 111.8% CAGR. Both numbers are exceptional. The stock holds at 28% of its 52-week range with RSI at 40. In other words, neither side has a clear edge right now. Revenue grows at 126.1% and profits at 111.8% CAGR, with D/E of 0.00. Meanwhile, the stock dips 12.4% in three months without any fundamental deterioration. Consequently, the stock quietly becomes cheaper relative to earnings power. For long-term investors, that is a feature. Check Fundamentals of Sai Parenterals Limited.